Scientists at Stony Brook University aim to create a caregiving robot assistant (CART) to help people with amyotrophic lateral sclerosis (ALS) and their caregivers with everyday tasks. Led by I.V. Ramakrishnan, PhD, a professor of computer science and associate dean at the university’s College of Engineering and Applied Sciences,…
News
May marks amyotrophic lateral sclerosis (ALS) awareness month, a time dedicated to raising awareness about ALS and answering the call to support those affected by the neurodegenerative disease. In the U.S. and internationally, baseball games, conferences, flag raisings, and community events are held during ALS Awareness Month to honor…
Having possible symptoms of amyotrophic lateral sclerosis (ALS) increases the chances of getting an ALS diagnosis by nearly five times, but getting diagnosed is more likely for people in urban areas, who have greater access to specialized care, a U.S. study shows. People in rural areas are diagnosed at…
While women with amyotrophic lateral sclerosis (ALS) see a faster functional decline, men have shorter survival times, mostly due to more rapid weight loss and lung function worsening, a study shows. The findings highlight the importance of considering sex-specific differences when studying the mechanisms leading to ALS and when…
The Gary E. Shealy Memorial ALS Clinic in Tennessee has received a $75,000 grant from the ALS Association to support expanding its clinical care services for people with amyotrophic lateral sclerosis (ALS). The clinic at East Tennessee State University (ETSU) Health is the only one in the state that…
Treatment with Qalsody (tofersen) in the real world slowed disease progression in people with amyotrophic lateral sclerosis (ALS) caused by SOD1 mutations, a small study reports. It also stabilized patients’ quality of life and lowered levels of nerve damage-related biomarkers, which is consistent with clinical trial data that…
A double-blind Phase 2 clinical trial that will test Corcept Therapeutics’ oral cortisol modulator dazucorilant against a placebo in people with amyotrophic lateral sclerosis (ALS) is now fully enrolled, the company announced in a press release. Called DAZALS (NCT05407324), the trial involves 249 adults with sporadic…
Treatment with NurOwn (debamestrocel), which BrainStorm Cell Therapeutics is developing for amyotrophic lateral sclerosis (ALS), may bring about changes in biomarkers of inflammation and neurodegeneration that predict clinical outcomes. The findings come from the Phase 3 trial (NCT03280056) that tested NurOwn against a placebo in 189 adults with rapidly…
Troriluzole, a new formulation of the approved amyotrophic lateral sclerosis (ALS) treatment riluzole, can be taken with or without food and appears to have better pharmacological properties than approved versions of the medication that allow once daily administration. That’s according to data from three studies in healthy volunteers presented…
NeuroSense Therapeutics’ investigational therapy PrimeC tends to reduce blood levels of neurofilament light chain (NfL), a biomarker of nerve damage, in people with amyotrophic lateral sclerosis (ALS) — especially when given earlier in the course of the disease. That’s according to data from the PARADIGM Phase 2b…
Recent Posts
- Actor Eric Dane honored for bringing visibility and hope to the ALS fight
- New ALS drug neflamapimod chosen for UK platform study
- Scientists find promising 3 drug combo for sporadic ALS using new models
- Small adjustments to a wheelchair can greatly improve comfort
- How ALS patients can show their stripes for Rare Disease Month